Concepedia

Author

Maria Greenwald

Desert Medical ImagingORCID

Also Known As

Charles H Pritchard, M GREENWALD, M Greenwald, M. Greenwald, M.W. Greenwald, MARIA GREENWALD, Maria Greenwald, Maria W Greenwald, Maria W. Greenwald, Maria White Greenwald

100

Publications

9.5K

Citations

35

H-Index

27

Concepts

All Affiliations

Desert Medical ImagingEli Lilly (United States)Stanford UniversityBone Health and Osteoporosis FoundationHôpital Cochin
MG

About

Maria Greenwald is an author at Desert Medical Imaging specializing in medicine, osteoporosis, and orthopaedics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

1.3K

2

Orthopaedics

6

6

1.1K

3

Obstetrics

4

4

267

4

Endocrinology

2

2

111

5

Health Sciences

1

1

12

Maria Greenwald

×

50

Publications

7.5K

Citations

33

H-Index

YearCitations

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald,

Arthritis & Rheumatism

2006

1.6K

Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Stanley Cohen, Robert M. Levy, Michael Keller,

Arthritis & Rheumatism

1999

615

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

Clifton O. Bingham, R. John Looney, Atul Deodhar,

Arthritis & Rheumatism

2009

458

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

Philip J. Mease, Mark C. Genovese, Maria Greenwald,

New England Journal of Medicine

2014

384

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen,

Annals of the Rheumatic Diseases

2016

375

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados,

The Lancet

2018

349

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

Reginster Jy, S. Adámi, Péter L. Lakatos,

Annals of the Rheumatic Diseases

2005

329

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

Edward Keystone, Paul Emery, Charles Peterfy,

Annals of the Rheumatic Diseases

2008

240

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

René Westhovens, Peter C. Taylor, Rieke Alten,

Annals of the Rheumatic Diseases

2016

227

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

Arthur Kavanaugh, Joel M. Kremer, L Ponce,

Annals of the Rheumatic Diseases

2016

226

Page 1